Hoth Therapeutics' HT-001 shows promising interim Phase 2a trial results, improving skin toxicities in cancer patients without treatment-related adverse effects.

Hoth Therapeutics (NASDAQ:HOTH) has entered into an exclusive licensing agreement to develop potential anti-obesity treatments based on technology co-developed by Emory University and the U.S ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Shares of Hoth Therapeutics HOTH skyrocketed 178.2% on Tuesday after the company announced positive interim safety and efficacy results from a mid-stage study of its lead candidate, HT-001 ...

At close: January 17 at 4:00:01 PM EST ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

(RTTNews) - Hoth Therapeutics (HOTH) has entered into an exclusive patent license agreement with the U.S. Department of Veterans Affairs, providing the company with exclusive rights to a jointly ...

NEW YORK, Dec. 26, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative therapies, today announced that it has entered into an ...

Hoth Therapeutics Inc. has entered into an exclusive patent license agreement with the U.S. Department of Veterans Affairs (VA), providing Hoth with exclusive rights to a jointly owned patent ...